e-ISSN: 2321-3647
logo

American Journal of Pharmacy and Health Research

Vamsi Krishna

Author Profile
2
Publications
2
Years Active
7
Collaborators
69
Citations

Publications by Vamsi Krishna

2 publications found • Active 2017-2022

2022

1 publication

Drug Targeting In Neoplastic Disorders

with D.Rama Brahma Reddy, K.Malleswari, Sudharani V, Navratha S
3/1/2022

The review on drug targeting in neoplastic disorders emphasizes the various targeting techniques for  effective treatment of the condition. Neoplasm refers to the new growth and its common in any individual, uncontrolled neoplasm results in condition called neoplastic disorder or tumor or cancer. Globally 14.1 million cancer cases were reported in 2012 and the number is expected to reach 24 million by 2035. This review outlines the advances in drug targeting to the neoplastic disorders  keeping in view on the highlights the novel drug delivery systems like liposomes and particulate system like nanoparticles  problems associated with conventional chemotherapy and radiation therapy. It usage in treatment of cancer and effective targeting ways to target the tumor cells without affecting the normal cells. 

2017

1 publication

A Review on Gene Expression of Monkey Pox Virus Infected Cells and Control The Disease

with K. Vamsi Krishna, Venkata Rohit Kumar Chandolu, J.N.Suresh Kumar
12/1/2017

ABSTRACTHuman monkey pox is an emerging viral zoonotic disease. This is caused by monkey pox virus. Monkey pox has a clinical presentation like flulike symptoms characteristic rash fever, malaise, back pain, and headache. Primarily monkey transmission to human is believed to occur through direct contact with infected animals (or) possibly by ingestion of inadequately cooked flesh. The review article mainly discuss about orthopox virus genes have been  shown to suppress anti-viral cell defenses, exploit host cell machinery and delay infection induced cell death. And control there are no licensed therapies to treat human monkey pox viral infection, however the small pox vaccine can protect against the disease. The management of monkey pox is mainly used this medications like Small Pox Vaccine, Cidofovir, Brincidofovir, Tecovirimat, Vaccinia Immune Globulin (VIG). Discontinuation of vaccination has given rise to increasing susceptibility to monkey pox viral infection. This lead to a fear of bioterrorism. Effective prevention limiting contact with infected patients (or) animal. Limiting the respiratory exposure to infected patients. Mortality and Morbidity rate of this virus is very rare conditions. This virus mainly prone to neonatal & pediatric patients, the hospital stay is minimum of 4 weeks. Keywords: Benign epidermal Monkey Pox (BEMP), Democratic Republic of the Congo (DRC), Monkey Pox Virus (MPV), Polymerase Chain Reaction (PCR), Immunoglobulin M (IgM), Center for Disease Control and Prevention (CDC), Fold Change Ratios (FCR), Ingenuity Pathway Analysis (IPA), Vaccinia Immune Globulin (VIG).